January 30 – February 1, 2024 | Boston, MA
DDR inhibitor development is evolving rapidly, marked by the continuous emergence of new targets.
AstraZeneca and Merck reaffirm their commitment to DDR inhibitors, yet more pharmaceutical companies like Roche and Gilead are diving into this therapeutic strategy; biotech companies like Artios and IDEAYA remain dedicated to delivering safe and effective treatments to patients.
The unmet need for cancer therapies reinforces the critical importance for the community to unite at the 7th Annual DDR Inhibitors Summit in Boston, in January 2024, to advance first-in-class oncology treatments for patients.
Beacon’s DDR Lead Research Analyst, Kieran Pinto, will be joining the expert speaker faculty, opening the conference to discuss ‘The Next Chapter of DDR Inhibitor Development Across Cancers‘. You can find more details about his session here or view the full agenda here.